Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Haematologica ; 104(1): 70-81, 2019 01.
Article in English | MEDLINE | ID: mdl-30171023

ABSTRACT

Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F myeloproliferative neoplasms. Recent studies have reported the presence of JAK2V617F in endothelial cells of some patients with myeloproliferative neoplasms. We investigated the role of endothelial cells that express JAK2V617F in thrombus formation using an in vitro model of human endothelial cells overexpressing JAK2V617F and an in vivo model of mice with endothelial-specific JAK2V617F expression. Interestingly, these mice displayed a higher propensity for thrombus. When deciphering the mechanisms by which JAK2V617F-expressing endothelial cells promote thrombosis, we observed that they have a pro-adhesive phenotype associated with increased endothelial P-selectin exposure, secondary to degranulation of Weibel-Palade bodies. We demonstrated that P-selectin blockade was sufficient to reduce the increased propensity of thrombosis. Moreover, treatment with hydroxyurea also reduced thrombosis and decreased the pathological interaction between leukocytes and JAK2V617F-expressing endothelial cells through direct reduction of endothelial P-selectin expression. Taken together, our data provide evidence that JAK2V617F-expressing endothelial cells promote thrombosis through induction of endothelial P-selectin expression, which can be reversed by hydroxyurea. Our findings increase our understanding of thrombosis in patients with myeloproliferative neoplasms, at least those with JAK2V617F-positive endothelial cells, and highlight a new role for hydroxyurea. This novel finding provides the proof of concept that an acquired genetic mutation can affect the pro-thrombotic nature of endothelial cells, suggesting that other mutations in endothelial cells could be causal in thrombotic disorders of unknown cause, which account for 50% of recurrent venous thromboses.


Subject(s)
Endothelial Cells/metabolism , Janus Kinase 2/biosynthesis , P-Selectin/biosynthesis , Thrombosis/metabolism , Animals , Disease Models, Animal , Endothelial Cells/pathology , Gene Expression Regulation, Enzymologic/drug effects , Humans , Hydroxyurea/pharmacology , Janus Kinase 2/genetics , Mice , Mice, Transgenic , P-Selectin/genetics , Thrombosis/drug therapy , Thrombosis/genetics , Thrombosis/pathology
2.
Biochem Pharmacol ; 84(8): 1014-23, 2012 Oct 15.
Article in English | MEDLINE | ID: mdl-22796565

ABSTRACT

Thrombospondin-1 (TSP-1) gives rise to fragments that have both pro- and anti-angiogenic effects in vitro and in vivo. The TSP-HepI peptide (2.3 kDa), located in the N-terminal domain of TSP-1, has proangiogenic effects on endothelial cells. We have previously shown that TSP-1 itself exhibits a dual effect on endothelial colony-forming cells (ECFC) by enhancing their adhesion through its TSP-HepI fragment while reducing their proliferation and differentiation into vascular tubes (tubulogenesis) in vitro. This effect is likely mediated through CD47 binding to the TSP-1 C-terminal domain. Here we investigated the effect of TSP-HepI peptide on the angiogenic properties of ECFC in vitro and in vivo. TSP-HepI peptide potentiated FGF-2-induced neovascularisation by enhancing ECFC chemotaxis and tubulogenesis in a Matrigel plug assay. ECFC exposure to 20 µg/mL of TSP-HepI peptide for 18 h enhanced cell migration (p < 0.001 versus VEGF exposure), upregulated alpha 6-integrin expression, and enhanced their cell adhesion to activated endothelium under physiological shear stress conditions at levels comparable to those of SDF-1α. The adhesion enhancement appeared to be mediated by the heparan sulfate proteoglycan (HSPG) syndecan-4, as ECFC adhesion was significantly reduced by a syndecan-4-neutralising antibody. ECFC migration and tubulogenesis were stimulated neither by a TSP-HepI peptide with a modified heparin-binding site (S/TSP-HepI) nor when the glycosaminoglycans (GAGs) moieties were removed from the ECFC surface by enzymatic treatment. Ex vivo TSP-HepI priming could potentially serve to enhance the effectiveness of therapeutic neovascularisation with ECFC.


Subject(s)
Endothelium, Vascular/cytology , Neovascularization, Physiologic/physiology , Thrombospondin 1/physiology , Animals , Cells, Cultured , Female , Flow Cytometry , Humans , Mice , Thrombospondin 1/chemistry
3.
Arterioscler Thromb Vasc Biol ; 31(3): 551-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21148423

ABSTRACT

OBJECTIVE: We examined whether plasma levels of angiogenic factors are altered in plasma of patients with peripheral arterial disease (PAD) and whether these factors affect endothelial progenitor cell-induced angiogenesis. METHODS AND RESULTS: Plasma was collected from 184 patients with PAD and 330 age-matched healthy controls. Vascular endothelial growth factor and placental growth factor concentrations did not differ between the groups, whereas we found a linear correlation between PAD disease and thrombospondin (TSP)-1 plasma level. TSP-1 was expressed in newly formed vessels in PAD patients having received local injections of bone marrow mononuclear cells. To analyze the functional role of TSP-1 during neoangiogenesis, we used a Matrigel-plug assay and showed that vascularization of implanted Matrigel-plugs was increased in TSP-1(-/-) mice. Moreover, injections of TSP-1 in C57Bl6/J mice after hindlimb ischemia induced a significant decrease of blood flow recovery. To investigate the effects of TSP-1 on human endothelial colony-forming cell (ECFC) angiogenic potential, recombinant human TSP-1 and a small interfering RNA were used. In vitro, TSP-1 N-terminal part significantly enhanced ECFC adhesion, whereas recombinant human TSP-1 had a negative effect on ECFC angiogenic potential. This effect, mediated by CD47 binding, modulated stromal cell-derived factor 1/CXC chemokine receptor 4 pathway. CONCLUSIONS: TSP-1 is a potential biomarker of PAD and ECFC-induced angiogenesis, suggesting that TSP-1 modulation might improve local tissue ischemia in this setting. ( CLINICAL TRIAL REGISTRATION: NCT00377897.).


Subject(s)
Angiogenic Proteins/blood , Endothelial Cells/metabolism , Ischemia/metabolism , Muscle, Skeletal/blood supply , Neovascularization, Physiologic , Peripheral Arterial Disease/blood , Stem Cells/metabolism , Thrombospondin 1/blood , Angiogenic Proteins/administration & dosage , Angiogenic Proteins/deficiency , Angiogenic Proteins/genetics , Animals , Biomarkers/blood , CD47 Antigen/metabolism , Case-Control Studies , Cell Adhesion , Cell Proliferation , Cells, Cultured , Chemokine CXCL12/metabolism , Disease Models, Animal , Endothelial Cells/transplantation , Hindlimb , Humans , Ischemia/physiopathology , Ischemia/surgery , Mice , Mice, Inbred C57BL , Mice, Knockout , Peripheral Arterial Disease/physiopathology , Peripheral Arterial Disease/surgery , Phenotype , Placenta Growth Factor , Pregnancy Proteins/blood , RNA Interference , Receptors, CXCR4/metabolism , Stem Cell Transplantation , Thrombospondin 1/administration & dosage , Thrombospondin 1/deficiency , Thrombospondin 1/genetics , Treatment Outcome , Vascular Endothelial Growth Factor A/blood
4.
Regen Med ; 6(1): 45-52, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21175286

ABSTRACT

AIMS: To assess the safety and feasibility of intra-arterial transplantation of autologous bone marrow mononuclear cells in patients with middle cerebral artery ischemic stroke within 90 days of symptom onset. PATIENTS & METHODS: Six patients were included in the study, and they received 1-5 × 10(8) bone marrow mononuclear cell and were evaluated using blood tests, neurological and imaging examination before treatment, and 1, 3, 7, 30, 60, 90, 120 and 180 days after transplantation. Scintigraphies were carried out 2 and 24 h after the procedure to analyze the biodistribution of labeled cells. Electroencephalogram was conducted within 7 days after transplantation. RESULTS: No patients exhibited any complication or adverse events during the procedure. There was no worsening in the neurological scales until the end of the follow-up. CONCLUSION: Intra-arterial bone marrow mononuclear cell transplantation is feasible and safe in patients with nonacute ischemic strokes of the middle cerebral artery. Further studies are required to evaluate the efficacy of this therapy.


Subject(s)
Bone Marrow Transplantation/adverse effects , Stroke/therapy , Adolescent , Adult , Aged , Bone Marrow Cells/cytology , Brain Ischemia/complications , Brain Ischemia/diagnostic imaging , Female , Humans , Injections, Intra-Arterial , Male , Middle Aged , Radionuclide Imaging , Stroke/diagnostic imaging , Stroke/etiology , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...